Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.

Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.

The manufacturing-units of Aarti Drugs Ltd. are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.

The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery.

Business area of the company

The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited.

Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

Aarti Drugs Ltd.

FDC Ltd.

Hikal Ltd.

Indoco Remedies Ltd.

AMI Organics Ltd.

Advanced Enzyme Technologies Ltd.

Wockhardt Ltd.

Glenmark Life Sciences Ltd.

Strides Pharma Science Ltd.

Caplin Point Laboratories Ltd.

Shilpa Medicare Ltd.

Marksans Pharma Ltd.

Sequent Scientific Ltd.

Jubilant Pharmova Ltd.

Unichem Laboratories Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	4,232 Cr		EPS	18.6		High	461.7
Stock P/E	24.6		Net Profit Margin	5.6		Low	453.05

AARTIDRUGS